J3393 Injection, betibeglogene autotemce
J-Codes
Also known as: betibeglogene autotemcel, Zolgensma, gene therapy
Betibeglogene autotemcel (Zolgensma) injection is a gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
Clinical Context
Autologous T cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Engineered cells modified with adenosine deaminase gene administered intravenously.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.